Old API Wind-down Ltd - Ordinary Shares ARLZQ

RE:RE:RE:RE:RE:Yosprala Approval

[kuatolives]

I liked the conference call inasmuch as they're treating it very professionally.  Nice to see Fibricor Rx's responding to the new salesforce, and its also good they're not just targetting any old bozo physician, but physicians more likely to perscribe yospralla, once launched.

Some other positives:

-Revenues should only expand from here and costs only shrink, but we'll see. This should translate into a steadily improving share price.

-No need for doing crazy deals like the Valeant's and Merus's of the world since debt fueled acquisition will not be the primary revenue driver going forward.

-Since the market has turned its back on debt in the pharma space, ARLZ may benefit from trader sentiment.

-A dollar a day price point for the end Yospralla user shouldn't be attracting too many bozo hedge fund managers launching patent attacks, in addition to the Hillary Clintons of the world waging war against it.  This allows ARLZ to quietly raise the price to insurers without big public displays of poor optics and people complaining about high costs. 

-The Canadian tax domicile (again) will make it a more attractive merger candidate for the Depomeds of the world if/when they can triple their market cap to stay within US Federal Treasury guidelines for mergers.
 
-Yosprala is heading to Europe and Canada so .... more $$.

Hopefully the worst of the cr@p is behind us and we can start seeing some green again.